Galmed just popped out of a downward trend that has been lasting several years. Galmed is an unprofitable micro cap ($94M) in the biotech space. It has less than $1M in revenue but it is showing strong revenue growth and is financially very healthy, so its fundamentals are strong and that's something that I personally like to see, even when I trade (should things...